Greenwich LifeSciences up as FDA removes clinical hold on cancer drug trial

Greenwich Lifesciences

12/07/2022 11:57

** Shares of Greenwich LifeSciences  GLSI.O  rises 7.4% to
$9.26 premarket
    ** FDA removes clinical hold, permitting late-stage trial of
co's experimental breast cancer therapy GLSI-100 to proceed
 urn:newsml:reuters.com:*:nBwbLbxPRa
    ** Co said in May FDA was conducting review of its
manufacturing plans and pharmacy procedures associated with hold
 urn:newsml:reuters.com:*:nBw8PCcNWa
    ** Stock down nearly two-thirds in value YTD, up to last
close

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))